Mpox has rapidly spread throughout the world. This study (A5418) is looking at the safety and efficacy of the medication, tecovirimat, for the treatment of Mpox infection. Participants with mild or moderate disease will be randomly assigned to receive tecovirimat OR placebo for 14 days. Participants will be guaranteed to receive tecovirimat who have severe disease.
Eligibility:
- Age 18 or older
- Confirmed or suspected Mpox for less than 14 days
- Present with at least one active (not yet scabbed) skin lesion, mouth lesion, or involvement of the anus or rectum
For more information, contact the UCLA Study Team at (310) 592-8127 or Maricela Gonzalez (Study Coordinator) at MMGonzalez@mednet.ucla.edu.
